EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis

Oncogene

Volumn 33, Issue 19, 2014, Pages 2454-2463

  Tanaka, M ^a   Suzuki, H I ^b   Shibahara, J ^a   Kunita, A ^a   Isagawa, T ^b   Yoshimi, A ^a   Kurokawa, M ^a   Miyazono, K ^b   Aburatani, H ^c   Ishikawa, S ^a   Fukayama, M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

EVI1; KRAS; microRNA; pancreatic cancer; PanIN

Indexed keywords

MICRORNA; MICRORNA 96; ONCOPROTEIN; UNCLASSIFIED DRUG; VIRAL INTEGRATION SITE 1 ONCOPROTEIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MUCINOUS CYSTIC NEOPLASM; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS CARCINOGENESIS; PRIORITY JOURNAL; TRANSCRIPTION TERMINATION; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRAL INTEGRATION SITE 1 ONCOGENE;

BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84900433466     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.204     Document Type: Article

References (46)

1. Hruban R, Boffetta P, Hiraoka N, Iacobuzio-Donahue C, Kato Y, Kern S et al. Tumours of the pancreas. In: Bosman F, Carneiro F, Hruban R, Theise N eds). WHO Classification of Tumours of the Digestive System. 4th edn, International Agency for Research on Cancer IARC): Lyon, 2010, pp 279-337.
2. Prasad NB, Biankin AV, Fukushima N, Maitra A, Dhara S, Elkahloun AG et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005; 65: 1619-1626.
3. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002; 123: 1052-1060.
4. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Goto M. Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci 2010; 17: 108-124.
5. Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 2011; 59: 942-952.
6. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683-695.
7. Hruban R, Pitman M, Klimstra D. Tuomrs of the pancreas. In: Silverberg S (ed). AFIP Atlas of Tumor Pathology. American Registry of Pathology: Washington DC, 2007, pp 51-164.
8. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-120.
9. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
10. De La OJ, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 2008; 105: 18907-18912.
11. Goyama S, Kurokawa M. Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 2009; 100: 990-995.
12. Yoshimi A, Kurokawa M. Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget 2011; 2: 575-586.
13. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005; 86: 127-141.
14. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933-2942.
15. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23: 4878-4884.
16. Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 2010; 70: 2115-2125.
17. Kwei KA, Bashyam MD, Kao J, Ratheesh R, Reddy EC, Kim YH et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet 2008; 4: e1000081.
18. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001; 97: 2815-2822.
19. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998; 394: 92-96.
20. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000; 19: 2958-2968.
21. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011; 117: 3617-3628.
22. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFbeta-and taxol-mediated cell death via PI3K/AKT. Oncogene 2006; 25: 3565-3575.
23. Gysin S, Lee SH, Dean NM, McMahon M. Pharmacologic inhibition of RAF-4MEK-4ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Canceer Res 2005; 65: 4870-4880.
24. Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl) 2010; 88: 1085-1094.
25. Suzuki HI, Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem 2011; 149: 15-25.
26. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
27. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011; 404: 896-902.
28. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-1392.
29. Gao JS, Zhang Y, Tang X, Tucker LD, Tarwater PM, Quesenberry PJ et al. The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett 2011; 585: 693-699.
30. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452.
31. Gomez-Benito M, Conchillo A, Garcia MA, Vazquez I, Maicas M, Vicente C et al. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2. Br J Cancer 2010; 103: 1292-1296.
32. De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K et al. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol 2011; 154: 337-348.
33. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010; 24: 447-463.
34. Senyuk V, Premanand K, Xu P, Qian Z, Nucifora G. The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One 2011; 6: e20793.
35. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 2010; 107: 9783-9788.
36. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70: 6015-6025.
37. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500-503.
38. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007; 67: 3074-3084.
39. Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N et al. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 2011; 96: 1448-1456.
40. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-733 e739.
41. Logsdon CD, Ji B. Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7: S40-S43.
42. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009; 137: 1072-10821082 e1-6.
43. Kitago M, Ueda M, Aiura K, Suzuki K, Hoshimoto S, Takahashi S et al. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer 2004; 110: 177-182.
44. Jimenez RE, Warshaw AL, Z'Graggen K, Hartwig W, Taylor DZ, Compton CC et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999; 230: 501-509, discussion 509-511.
45. Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immuno-phenotype to anaplastic large cell lymphoma. Blood 2011; 118: 6881-6892.
46. Sentani K, Oue N, Tashiro T, Sakamoto N, Nishisaka T, Fukuhara Tea. Immuno-histochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol 2008; 32: 1182-1189.